May 6, 2020 / 11:44 AM / a month ago

BRIEF-Bristol Myers Squibb Provides Update On Biologics License Application For Lisocabtagene Maraleucel

May 6 (Reuters) - Bristol-Myers Squibb Co:

* BRISTOL MYERS SQUIBB PROVIDES UPDATE ON BIOLOGICS LICENSE APPLICATION (BLA) FOR LISOCABTAGENE MARALEUCEL (LISO-CEL)

* BRISTOL-MYERS SQUIBB CO - NEW PRESCRIPTION DRUG USER FEE ACT (PDUFA) ACTION DATE SET BY FDA IS NOVEMBER 16, 2020.

* BRISTOL-MYERS SQUIBB CO - FDA EXTENDED ACTION DATE BY THREE MONTHS FOR BIOLOGICS LICENSE APPLICATION FOR LISOCABTAGENE MARALEUCEL

* BRISTOL-MYERS SQUIBB CO - COMPANY SUBMITTED ADDITIONAL INFORMATION TO FDA, WHICH WAS DEEMED TO CONSTITUTE A MAJOR AMENDMENT TO APPLICATION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below